文献速递骨质疏松与代谢性骨病

教育激励支持项目显著提高特立帕肽两年持续用药率

Two-year persistence with teriparatide improved significantly after introduction of an educational and motivational support program.
PubMed 文献 · Osteoporos Int · 2019-07-18

本研究评估荷兰1573例接受特立帕肽治疗的重度骨质疏松患者。采用教育激励支持项目(EMSP)的患者两年持续用药率为78%,高于基础支持项目(BSP)的72%;EMSP组因副作用停药比例显著低于BSP组(8% vs 15%,p<0.001);EMSP组不持续用药风险较BSP组低28%(HR 0.72,95%CI 0.55-0.93)。

要点

  • EMSP组两年持续用药率78%,BSP组72%。
  • EMSP组因副作用停药比例8%,显著低于BSP组的15%(p<0.001)。
  • EMSP组不持续用药风险较BSP组低28%(HR 0.72,95%CI 0.55-0.93)。

核心结论

  • 引入EMSP可提高重度骨质疏松患者特立帕肽治疗的持续用药率,78%的患者在两年治疗期内持续用药。

研究设计与样本

  • 评估2013年1月至2018年1月期间接受特立帕肽治疗的1573例荷兰患者。
  • 2013年1月起所有患者接受基础支持项目(BSP),包括教育性家访启动治疗及第1、2.5、8周电话随访。
  • 2015年5月起所有患者接受EMSP,即在BSP基础上增加电话中用药依从性评估、第12个月额外电话及第9、14个月激励信件。

主要发现

  • EMSP组两年持续用药率为78%,BSP组为72%,EMSP组统计学显著更高。
  • 除因副作用停药比例外,两组停药原因相当。
  • EMSP组因副作用停药比例为8%,BSP组为15%(p<0.001),EMSP组显著更低。
  • EMSP组不持续用药风险较BSP组低28%(HR 0.72,95%CI 0.55-0.93)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: This study evaluated the 2-year persistence with teriparatide in the Netherlands. Analyses showed that the risk of non-persistence was 28% lower in patients who were followed according to an additional educational and motivational support program. INTRODUCTION: Until recently, teriparatide (TPTD) was a third-line treatment option for severe osteoporosis in the Netherlands, which could only be prescribed by medical specialists based on a specific medical statement. We aimed to determine whether an educational and motivational support program (EMSP) increased 2-year treatment persistence with TPTD in patients with severe osteoporosis. METHODS: We evaluated persistence in 1573 Dutch patients treated with TPTD from January 2013 until January 2018. From January 2013 onwards, all patients received a basic support program (BSP) consisting of an educational home visit to initiate TPTD treatment and phone calls (at 1, 2.5 and 8 weeks). Since May 2015, all patients received the EMSP consisting of the BSP extended with evaluation of medication adherence during phone calls, an additional phone call (at 12 months), and motivational letters at 9 and 14 months. RESULTS: The EMSP showed a statistically significantly higher 2-year persistence (78%) with TPTD as compared with the BSP (72%). Reasons for treatment discontinuation were comparable between groups, except for the proportion of patients who had stopped TPTD administration due to side effects, which was significantly lower in the EMSP group (8% vs. 15% in BSP, p < 0.001). Overall, the risk of non-persistence was 28% lower in the EMSP compared with the BSP group (HR: 0.72; 95% CI: 0.55-0.93). CONCLUSION: The introduction of the EMSP has demonstrated to improve the persistence with TPTD, resulting in 78% of the patients being persistent with TPTD during the 2-year treatment period.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. van Maren MA, Wyers CE, Driessen JHM, et al. Two-year persistence with teriparatide improved significantly after introduction of an educational and motivational support program. Osteoporos Int. 2019. PMID: 31321446. doi:10.1007/s00198-019-05052-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。